Mangoceuticals, a company that sells medicines online, said it had teamed up with drugmakers Eli Lilly and Novo Nordisk to offer popular weight loss injections. This news made their stock price go up at first. However, both Eli Lilly and Novo Nordisk quickly said this was not true, and Mangoceuticals’ stock price then dropped. Mangoceuticals had announced that members of their MangoRx Direct and PeachesRx Direct programs would be able to get Lilly’s Zepbound and Novo’s Wegovy through LillyDirect and NovoCare Pharmacy, which are the companies’ online pharmacies. But Eli Lilly said they have no connection to Mangoceuticals and even sued them last year. Novo Nordisk also said they had no agreement with Mangoceuticals. Despite this, Eli Lilly did say that any doctor, including those working with telehealth platforms, can prescribe their medicines and send the prescription to LillyDirect. Mangoceuticals did not respond to requests for comment. The news had initially excited investors, with the stock rising 21% to $2.18 on November 13. But after the drugmakers denied the partnership, the stock price fell to $1.19 by the end of the day, which was even lower than the previous day’s close of $1.76. The company is worth about $67.7 million. Despite the controversy, Mangoceuticals is focusing on selling branded versions of GLP-1RA drugs. The FDA has been trying to stop telehealth providers from selling compounded versions of these drugs, which are now only allowed if they are personalized for a specific patient. This news comes after recent price changes for Zepbound and Wegovy in the US. Weight loss and diabetes drugs have been affected by pricing reforms introduced by the Trump administration. Just last week, Novo Nordisk and Eli Lilly made deals with the White House to lower the prices of their GLP-1RA drugs.